1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Kazia Therapeutics Limited
  6. News
  7. Summary
    KZA   AU000000KZA9

KAZIA THERAPEUTICS LIMITED

(KZA)
  Report
Delayed Australian Stock Exchange  -  02:11 2022-08-19 am EDT
0.2500 AUD    0.00%
08/08Kazia Therapeutics Validates Response of Cancer Drug on Brain Metastases; Shares Jump 8%
MT
08/05Kazia Therapeutics Says Paxalisib Effective in Brain Metastases During Phase 1 Trial; Shares Rise
MT
08/05KAZIA THERAPEUTICS : REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kazia Therapeutics Limited - PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT

06/08/2022 | 07:47am EDT

Sydney - Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncologyfocused drug development company, is pleased to announce that a phase II, genomicallyguided study of multiple therapies in patients with brain metastases, led by the Alliance for Clinical Trials in Oncology (NCT03994796), has advanced the paxalisib arm to an expansion stage in breast cancer, following completion of the pre-specified interim analysis.

Key Points

The Alliance study, also known as A071701, commenced enrolment in 2019. The study is recruiting patients with brain metastases (cancer that has spread to the brain from elsewhere in the body) from breast cancer, lung cancer, or other primary tumors. Patients are assigned to receive either abemaciclib (Lilly), entrectinib (Genentech), or paxalisib (Kazia), depending on the genetic profile of their tumor. * The study is sponsored by the Alliance for Clinical Trials in Oncology, a U.S.-based cancer research network sponsored by the National Cancer Institute. Kazia has supported the study with a financial grant, and with provision of paxalisib study drug. * For each drug - tumor combination (e.g., paxalisib in patients with lung cancer brain metastases), the study envisages an initial stage of ten patients for each subgroup (i.e., breast, lung, other). If the pre-specified response criteria are met at the interim analysis of ten patients per subgroup, the study expands that drug-tumor combination to enroll eleven additional patients, in order to seek definitive efficacy data. * The paxalisib arm has fully recruited the breast cancer cohort for the initial prespecified interim analysis and has met the threshold for transition to the expansion stage of the study. * The initial stage of the study remains ongoing for paxalisib in lung cancer and in other tumors.

'Brain metastases are a complication of several common cancers, and effective treatments remain elusive,' said Priscilla Brastianos, MD, Principal Investigator of the study, and Associate Professor of Medicine at Harvard Medical School. 'This study has been designed to identify potential new therapies for patients with brain metastases, using leading genomic techniques to assign patients to the most appropriate treatment. We are looking forward to continuing our exploration of paxalisib in this important disease area.'

Brain Metastases

Up to 30% of patients with metastatic cancer will develop secondary tumors (metastases) in the brain, and it is estimated that there are approximately 200,000 new cases of brain metastases each year in the United States alone. Treatment options remain limited, and average survival of patients with brain metastases ranges from 3 to 27 months, depending on factors such as the location of the original tumor.

It is increasingly recognized that cancer is a complex disease, in which tumors in a similar location (e.g., breast, lung) may respond very differently to treatment. An important factor in this is the genetic profile of the tumor. Clinical studies have begun to focus on carefully allocating patients to treatment on basis of this genetic profile, an approach which is sometimes referred to as 'precision medicine' or 'personalized medicine'. The Alliance study is an example of this approach.

Contact:

Australia

Jane Lowe

IR Department

E: jane.lowe@irdepartment.com.au

Phone: +61 411 117 774

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immunooncology agents. A phase I study commenced recruitment in November 2021.

About the Alliance for Clinical Trials in Oncology

The Alliance for Clinical Trials in Oncology (Alliance) is a clinical trials network that involves approximately 10,000 physicians across the United States and Canada. The Alliance seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. It is part of the National Clinical Trials Network (NCTN) sponsored by the National Cancer Institute (NCI).

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as 'may,' 'intend,' 'potential,' 'prospective,' or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements. Such statements are based on Kazia's expectations and projections about future events and future trends affecting our business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical trials and product development and the impact of global economic conditions. These and other risks and uncertainties, are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings to SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. Actual results could differ materially from those discussed in this announcement.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
KAZIA THERAPEUTICS LIMITED 0.00% 0.25 Delayed Quote.-80.08%
ROCHE HOLDING AG 1.06% 323.35 Delayed Quote.-15.60%
All news about KAZIA THERAPEUTICS LIMITED
08/08Kazia Therapeutics Validates Response of Cancer Drug on Brain Metastases; Shares Jump 8..
MT
08/05Kazia Therapeutics Says Paxalisib Effective in Brain Metastases During Phase 1 Trial; S..
MT
08/05KAZIA THERAPEUTICS : REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WI..
PU
08/05Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical..
CI
08/02HC Wainwright Downgrades Kazia Therapeutics to Neutral From Buy
MT
08/02Maxim Downgrades Kazia Therapeutics to Hold From Buy
MT
08/01Top Midday Decliners
MT
08/01Kazia Therapeutics' GBM AGILE Pivotal Study Fails to Meet Pre-Defined Criteria for 2nd ..
MT
08/01KAZIA THERAPEUTICS : PROVIDES PROGRESS UPDATE ON GBM AGILE PIVOTAL STUDY - Form 6-K
PU
08/01Top Premarket Decliners
MT
More news
Analyst Recommendations on KAZIA THERAPEUTICS LIMITED
More recommendations
Financials
Sales 2022 0,27 M 0,19 M 0,19 M
Net income 2022 -27,0 M -18,6 M -18,6 M
Net cash 2022 7,50 M 5,15 M 5,15 M
P/E ratio 2022 -1,22x
Yield 2022 -
Capitalization 37,4 M 25,7 M 25,7 M
EV / Sales 2022 109x
EV / Sales 2023 106x
Nbr of Employees -
Free-Float 92,1%
Chart KAZIA THERAPEUTICS LIMITED
Duration : Period :
Kazia Therapeutics Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KAZIA THERAPEUTICS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,25 AUD
Average target price 0,45 AUD
Spread / Average Target 80,0%
EPS Revisions
Managers and Directors
James Garner Chief Executive Officer, MD & Executive Director
Gabrielle Heaton Director-Finance & Administration
Karen R. Krumeich Chief Financial Officer
Iain Gladstone Ross Chairman
John E. Friend Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
KAZIA THERAPEUTICS LIMITED-80.08%26
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689
IQVIA HOLDINGS INC.-15.28%44 542
SEAGEN INC.11.04%31 186
ALNYLAM PHARMACEUTICALS, INC.31.77%26 820